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Abstract
Introduction: Mild induced hypothermia (MIH) is believed to reduce mortality and neurological impairment after
out-of-hospital cardiac arrest. However, a recently published trial demonstrated that hypothermia at 33 °C did not
confer a benefit compared with that of 36 °C. Thus, a systematic review and meta-analysis of randomised controlled
trials (RCTs) was made to investigate the impact of MIH compared to controls on the outcomes of adult patients
after cardiac arrest.
Methods: We searched the following electronic databases: PubMed/MEDLINE, the Cochrane Library, Embase, the
Web of Science, and Elsevier Science (inception to December 2014). RCTs that compared MIH with controls with
temperature >34 °C in adult patients after cardiac arrest were retrieved. Two investigators independently selected
RCTs and completed an assessment of the quality of the studies. Data were analysed by the methods
recommended by the Cochrane Collaboration. Random errors were evaluated with trial sequential analysis.
Results: Six RCTs, including one abstract, were included. The meta-analysis of included trials revealed that MIH did
not significantly decrease the mortality at hospital discharge (risk ratio (RR) = 0.92; 95 % confidence interval (CI),
0.82–1.04; p = 0.17) or at 6 months or 180 days (RR = 0.94; 95 % CI, 0.73–1.21; p = 0.64), but it did reduce the
mortality of patients with shockable rhythms at hospital discharge (RR = 0.74; 95 % CI, 0.59–0.92; p = 0.008) and at
6 months or 180 days. However, MIH can improve the outcome of neurological function at hospital discharge
(RR = 0.80; 95 % CI, 0.64–0.98; p = 0.04) especially in those patients with shockable rhythm but not at 6 months or
180 days. Moreover, the incidence of complications in the MIH group was significantly higher than that in the
control group. Finally, trial sequential analysis indicated lack of firm evidence for a beneficial effect.
Conclusion: The available RCTs suggest that MIH does not appear to improve the mortality of patients with cardiac
arrest while it may have a beneficial effect for patients with shockable rhythms. Although MIH may result in some
adverse events, it helped lead to better outcomes regarding neurological function at hospital discharge. Large-scale
ongoing trials may provide data better applicable to clinical practice.
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Introduction
Millions of people suffer sudden cardiac arrest (CA) every
year in the whole world, often related to coronary heart
disease. The global incidence of out-of-hospital cardiac ar-
rest (OHCA) is about 82.9 per 100,000 population within
all age groups, and 213.1 per 100,000 population in adult
groups [1]. Return of spontaneous circulation (ROSC) is
achieved in 25 % to 40 % of the patients [2, 3]. However,
the mortality and risk of neurological impairment is high.
Global brain ischemia and the reperfusion injury following
resuscitation may lead to brain tissue degeneration and
loss of neurological function [4].
The 2010 guidelines of the American Heart Association
recommend mild induced hypothermia (MIH; 32–34 °C)
as an important part of resuscitation for patients who have
experienced CA [5]. Two randomised controlled trials
(RCTs) have shown the beneficial effects of MIH in the
improvement of survival and neurological outcomes of pa-
tients following CA [6, 7]. In addition, it has been shown
in rats that hypothermia protects brain regions that dis-
play rapid as well as delayed neuronal damage and that a
minimal time of hypothermia is necessary for effective
neuronal protection [8]. However, MIH also interferes
with numerous physiological and pathological processes
and might induce unfavourable effects, such as cardiac
dysrhythmia and coagulopathy [7, 9]. Recently, many
scholars have questioned the temperature and the efficacy
of MIH and have criticised previous trials that showed
that MIH improved the mortality of patients with OHCA
because they had high risks of bias [10]. Nielsen and col-
leagues have shown that in unconscious survivors of
OHCA of presumed cardiac origin, hypothermia at a tar-
geted temperature of 33 °C did not confer a benefit com-
pared with a targeted temperature management of 36 °C
[11]. Although MIH has been implemented as the stand-
ard care for patients after CA in many countries, the
evidence for its possible beneficial effects are still contro-
versial. Thus, the object of this systematic review and
meta-analysis was to evaluate the impact of MIH com-
pared to controls with temperature >34 °C in adult pa-




We included trials with the following features:
1) Type of study: Randomised controlled clinical trials
2) Population: Adult patients (aged more than
18 years) who suffered from CA (regardless whether
in-hospital CA (IHCA) or OHCA) and who were
successfully resuscitated
3) Intervention: MIH (any body target temperature
≤34 °C)
4) Control (treatment according to the standard
treatment after CA in any body temperature
>34 °C with or without temperature intervention)
5) The following outcomes were included. a) Primary
outcomes: mortality at hospital discharge, mortality
at 6 months or 180 days and long-term (more than
1 year); b) secondary outcomes: neurological
function during hospital stay and 6 months or
180 days in cerebral performance categories
(CPC) and adverse events.
Search strategy for the identification of studies
We conducted a search of the following databases until
December 2014: Medline, Embase, Cochrane (Central)
database, Elsevier, Web of Science and ClinicalTrials.gov
(inception to December 2014). Searches were conducted
as described by Nielsen et al. [10] and Arrich et al. [12]
(see Additional file 1: Tables S1 and S2). There was no
language restriction.
Study selection
Two reviewers independently screened titles and ab-
stracts to determine whether a particular study met the
inclusion criteria. The full texts of the articles were then
reviewed independently according to the inclusion and
exclusion criteria. Any discrepancies were resolved by a
consensus on the inclusion or exclusion of a particular
study after a discussion with a third reviewer.
Data extraction and management
Two reviewers independently extracted data using a
standardised data extraction protocol. Any disagree-
ments between the two reviewers were resolved by a
discussion, whereby a consensus was then reached.
The relevant outcomes were mortality, neurological
function and adverse events potentially related to
MIH. Neurological function was evaluated according
to CPC, where a CPC score of 1 and 2 was defined
as a good neurological outcome and a score of 3–5
was defined as a poor neurological outcome. We
further defined outcome at discharge as short-term
outcome and outcome at 6 months as long-term
outcome.
Methodological risk of bias assessment
We summarised the evidence applying GRADE levels
[13] (high, moderate, low, and very low) by evaluating
design, quality, consistency, precision, directness and
possible publication bias of the included trials using
GRADEpro Guideline Development Tool.
We assessed random sequence generation, allocation
concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome
data and selective reporting to assess the internal validity
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of the identified trials according to the Cochrane
Handbook [14].
Sensitivity analyses were used to assess the impact of
study quality issues on the overall effect estimate and
the effect size of all identified trials when neglecting het-
erogeneity and publication status conducted by STATA
11.0 (Stata Corporation, College Station, TX, USA).
Subgroup meta-analysis
A subgroup meta-analysis was performed to determine
the effect of the initial rhythms (shockable and non-
shockable rhythms) on the efficiency of MIH with regard
to the outcomes of patients with CA. The articles with-
out specific classification of initial rhythms were classi-
fied into shockable and non-shockable rhythm groups.
In all included studies, we also performed meta-
analysis to compare the effects between MIH and no tar-
get temperature (any body temperature >34 °C without
cooling or warming methods) on the outcomes of adult
patients after CA. Moreover, meta-analysis of the effects
between MIH and target temperature management
(TTM; any body temperature >34 °C with cooling or
warming methods) on the outcomes of adult patients
after CA was also performed.
Statistical analysis
The meta-analysis of the effect of MIH on outcomes in
patients with CA was conducted using the methods rec-
ommended by the Cochrane Collaboration software Rev-
Man 5.3 (The Nordic Cochrane Centre, Rigshospitalet,
Copenhagen, Denmark). The statistical heterogeneity
and inconsistency were measured and quantified by the
Mantel-Haenszel (M-H) chi-square test and the I2 test
in RevMan 5.3 [15]. The statistically significant hetero-
geneity was predefined as p < 0.10 with the M-H chi-
square test. In addition, I2 index was used to assess
heterogeneity in the meta-analysis. Higgins and col-
leagues proposed 25 %, 50 % and 75 % of I2 values would
mean low, medium and high heterogeneity, respectively
[15]. In cases of obvious heterogeneity (i.e., p < 0.10 with
M-H test; I2 > 50 %), the meta-analysis employed the
random-effects model; otherwise, the meta-analysis used
the fixed-effects model. We reported a risk ratio (RR)
with 95 % confidence interval (CI) for the dichotomous
data and weighted mean differences with 95 % CIs for
the continuous data. The publication bias was evaluated
by visual inspection of the funnel plot.
Due to type I errors which result from an increased
risk of random error and repeated significance testing
[16, 17], we used trial sequential analysis (TSA; TSA
software version 0.9 Beta; Copenhagen Trial Unit,
Copenhagen, Denmark), which combines information
size estimation with an adjusted threshold for statistical
significance in the cumulative meta-analysis [16–18].
Information size was calculated as diversity-adjusted in-
formation size (DIS) [19], suggested by the relative risk
reduction (RRR) of the intervention in the included
trials.
Results
Summary of the studies
The flow diagram that shows the identification of studies
throughout the review is illustrated in Fig. 1. Overall, we
identified 4699 papers and excluded 4645 after screening
the titles and abstracts for the terms “hypothermia”,
“cardiac arrest” and “randomised control trial”. We re-
trieved 54 articles that were full-length manuscripts and,
finally, six were included in this meta-analysis.
These six trials included 1417 patients. The sub-
jects who were included were adult patients with CA
who were randomised to MIH of 32–34 °C versus
control intervention. A total of 730 subjects received
hypothermia therapy while the remainder were in
the control group. The methods of hypothermia
therapy included external cooling, the use of an
intravascular cooling device and continuous renal re-
placement therapy (CRRT). One study did not report
the method of cooling [20]. Among all the included
studies, three studies followed the patients for
6 months [7, 11, 21], and the others followed the pa-
tients for 14 days [22], 1 month [20] or until hos-
pital discharge [6]. The main characteristics of the
included studies are shown in Table 1.
Random errors
TSA was calculated with α = 0.05 and β = 0.20 (power
80 %) and a required diversity-adjusted information size
based on the intervention effect suggested by the in-
cluded trials using a fixed-effects model (RRR of 5.8 %
regarding mortality and 16,287 patients) and a random-
effects model (RRR of 7.29 % regarding poor neuro-
logical function and 15,568 patients). TSA indicated lack
of reliable and conclusive evidence for a beneficial effect
of MIH for both mortality (Fig. 2a) and a poor neuro-
logical outcome (Fig. 2b), since the monitoring boundaries
were not finally surpassed and the required information
size was not reached.
Impact on mortality
Among the included studies, five studies of 1363 pa-
tients reported the mortality at hospital discharge and
were included in the primary analysis. We detected no
evidence of a publication bias after a funnel plot analysis
(Additional file 2: Figure S1a). There was statistically in-
significant heterogeneity (p = 0.24) and medium hetero-
geneity (I2 = 28 %) among all mortality at discharge
analyses (Fig. 3a). The mortality rate was not signifi-
cantly different between the MIH group and the control
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group (RR = 0.92; 95 % CI, 0.82–1.04; p = 0.17). However,
a subgroup analysis showed that MIH could reduce the
mortality of patients who had shockable rhythms and
cardiac arrest (n = 352; RR = 0.74; 95 % CI, 0.59–0.92;
p = 0.008). The RR of mortality for patients with non-
shockable rhythms who received MIH versus those
who did not (control group) was 0.87 (n = 30; 95 %
CI, 0.66–1.15; p = 0.34).
Among the included studies, only three studies of
1256 patients reported the mortality at 6 months or
180 days. We detected no evidence of a publication bias
after a funnel plot analysis (Additional file 2: Figure
S1b), but there was significant heterogeneity (p = 0.06)
and substantial heterogeneity (I2 = 65 %) among the
trials (Fig. 3b). Mortality at 6 months or 180 days was
not reduced in patients treated with MIH compared to
control (RR = 0.94; 95 % CI, 0.73–1.21; p = 0.64). How-
ever, a subgroup analysis showed that MIH could reduce
the mortality at 6 months or 180 days of patients who
had shockable rhythms (n = 275; RR = 0.74; 95 % CI,
0.58–0.95; p = 0.02).
Impact on neurological function
The overall effect of MIH on neurological function at
hospital discharge was estimated from five trials, which
included a total of 1372 patients. No evidence of a publi-
cation bias was observed following a funnel plot assess-
ment (Additional file 3: Figure S2a), but there was
significant heterogeneity (p = 0.002) and substantial het-
erogeneity (I2 = 76 %) among the trials (Fig. 4a). Based
on a random-effects model, we found that MIH pro-
motes better outcomes of neurological function at hos-
pital discharge (RR = 0.80; 95 % CI, 0.64–0.98; p = 0.04).
Interestingly, similar to the effect of MIH on mortality,
the subgroup analysis showed that MIH could also
improve the neurological function of patients with
shockable rhythms (n = 350; RR = 0.73; 95 % CI, 0.60–
0.88; p = 0.001), but not those with non-shockable
rhythms (n = 30; RR = 0.88; 95 % CI, 0.77–1.10; p = 0.26).
The overall effect of MIH on neurological function at
6 months or 180 days was estimated from only three
trials of 1348 patients. No evidence of a publication
bias was observed following a funnel plot assessment
Fig. 1 Flow diagram of the study selection
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Table 1 Characteristics of the included trials
Duration Participants Experimental
intervention








Not reported OHCA patients with
GCS <8
MIH to 32–34 °C








OHCA and GCS <8 Not defined 1 month Not reported 54
Hachimi-Idrissi
2001 [22]
6 months Unconscious OHCA
patients, cardiac cause
of arrest, initial rhythm
asystole of PEA
Helmet cooling to 34 °C,
when temperature of
34 °C achieved or more
than 4 h elapsed from
start of cooling, passive







PEA as initial rhythm,
>18 years, temp








14 days Not reported 30
HACA 2002 [7] 65 months Unconscious CA
patients, cardiac cause
of arrest, initial rhythm
VF or non-perfusing VT
Air cooling induced
hypothermia to 33 °C
for 24 h, passive







VT as initial rhythm,
18–75 years, 5–15
min from arrest to












study, CA after arrival
of medical personnel
6 months 3551 275
Bernard 2002 [6] 33 months Unconscious OHCA
patients, cardiac cause
of arrest, initial rhythm
VF or VT
Ice-pack induced
hypothermia to 33 °C







OHCA with VF as
initial rhythm,
persistent coma
<18 years for men,




causes of coma than







Laurent 2005 [21] 23 months Unconscious OHCA
patients, cardiac cause
of arrest, initial rhythm
VF or asystole
CVVH to 32–33 °C





37 °C for 8 h, thereafter
no temperature control
OHCA of cardiac
origin, VF of asystole,
18–75 years, <10 min
to start of CPR,














Table 1 Characteristics of the included trials (Continued)
Nielsen 2013 [11] 27 months OHCA patients with
GCS <8





to 33 °C for 28 h,
gradual rewarming to
37 °C in hourly
increments of 0.5 °C,
<37.5 °C for unconscious







to 36 °C for 28 h,
gradual rewarming
to 37 °C in hourly
increments of 0.5 °C,
<37.5 °C for
unconscious patients
until 72 hours after CA
OHCA of cardiac
origin, GCS <8,




An interval from the
ROSC to screening
>240 min, unwitnessed






180 days 950 939
CA Cardiac arrest, CNS Central nervous system, CPR Cardiopulmonary resuscitation, CVVH Continuous veno-venous filtration, GCS Glasgow Coma Score, HACA Hypothermia After Cardiac Arrest, ICU Intensive care unit,
MAP Mean arterial pressure, MIH Mild induced hypothermia, OHCA Out-of-hospital cardiac arrest, PEA Pulseless electrical activity, ROSC Return of spontaneous circulation, SBP Systolic blood pressure, VF Ventricular fibril-









Fig. 2 (See legend on next page.)
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(Additional file 3: Figure S2b), but there was signifi-
cant heterogeneity (p = 0.03) and substantial hetero-
geneity (I2 = 72 %) among the trials (Fig. 4b). MIH did
not promote better outcomes of neurological function
at 6 months or 180 days based on a random-effects
model (RR = 0.94; 95 % CI, 0.72–1.23; p = 0.67). How-
ever, the subgroup analysis showed that MIH could
also improve the neurological function of patients
with shockable rhythms (n = 273; RR = 0.74; 95 % CI,
0.59–0.93; p = 0.01).
Impact on complications
Five trials reported the adverse effects of MIH but
only four of them were evaluated to estimate the
overall effect of MIH on the incidence of complica-
tions (Fig. 5) because the trial of Bernard et al. [6]
did not report the incidence of the complications.
The complications associated with MIH that were re-
ported in the trials included pneumonia, sepsis, and
arrhythmia, among others. The incidence of complications
in the MIH group was significantly higher than that in the
control group (RR = 1.14; 95 % CI, 1.05–1.25; p = 0.003).
No evidence of a publication bias was observed following
a funnel plot assessment (Additional file 4: Figure S3).
Risk of bias in included studies
We assessed each included trial by the mode of
randomization, allocation concealment, level of blinding
and loss to follow-up (Fig. 6).
Summary of evidence according to GRADE
Randomised trials are rated high on the GRADE scale.
There were variable risks of bias in all the trials, leading us
to downgrade the quality of the evidence. Due to one trial
[11], there was some inconsistency among the trials. One
trial [7] included only less than 8 % of the screened patients
and one trial [22] included only CA patients with pulseless
electrical activity and asystole. Our application of GRADE
methodology led us to conclude that the accumulated
evidence is of low quality for mortality and neurological
outcome. For a GRADE profile see Tables 2 and 3.
Sensitivity analysis
As shown in Fig. 7a and b, the study conducted by
Nielsen et al. [11] was completely out of range of the
others and probably contributed to the heterogeneity, in-
dicating lack of reliability in our conclusions.
Impact of MIH versus no target temperature on mortality
and neurological function of CA patients
Among the included studies, four studies of 423 patients
reported the mortality and four studies of 421 patients re-
ported neurological function at 6 months and at hospital
discharge. We detected no evidence of a publication bias
after a funnel plot analysis (Additional file 5: Figure S4a
and b). The mortality rate was significantly different
between the MIH group and the no target temperature
group (RR = 0.77; 95 % CI, 0.65–0.92; p = 0.003), and so
was the neurological function between them (RR = 0.76;
95 % CI, 0.65–0.89; p < 0.001) (Additional file 6: Figure
S5a and b).
Impact of MIH versus TTM on mortality and neurological
function of CA patients
Among the included studies, only two studies of 980 pa-
tients reported the mortality and three studies of 1029
patients reported neurological function at the end of
trial and at hospital discharge. We detected no evidence
of a publication bias after a funnel plot analysis, but
there was significant heterogeneity (p = 0.005) and
substantial heterogeneity (I2 = 81 %) among the trials
in the effect on neurological function (Additional file 7:
Figure S6a and b). The mortality rate was not significantly
different between the MIH group and the TTM group
(RR = 1.03; 95 % CI, 0.91–1.16; p = 0.67), and neither was
the neurological function between them (RR = 0.89;
95 % CI, 0.59–1.35; p = 0.58) (Additional file 8: Figure
S7a and b).
(See figure on previous page.)
Fig. 2 a. Trial sequential analysis for a relative risk reduction of all-cause mortality of 5.8 % of hypothermia after cardiac arrest in five trials
with 1363 patients reporting mortality. A required diversity-adjusted information size of 16,287 patients was calculated based on a control
event proportion of 51.0 %, a hypothermia-induced relative risk reduction of mortality of 5.8 % suggested by all trials, α = 0.05 two-sided,
β = 0.20 (power = 80 %), and diversity D2 = 60 %. The cumulated Z-curve (blue) crosses the traditional boundary (p = 0.05) but not the trial
sequential monitoring boundary, indicating lack of firm evidence for a beneficial effect of 5.8 % relative risk reduction of the intervention
when the analysis is adjusted for repetitive testing on accumulating data. There is insufficient information to reject or detect an intervention effect of
5.8 % relative risk reduction of all-cause mortality as the required information size is not yet reached. b. Trial sequential analysis (TSA) for a relative risk
reduction of 7.29 % of hypothermia after cardiac arrest in six trials with 1409 patients reporting neurological function. A required diversity-adjusted
information size of 15,568 patients was calculated based on a control event proportion of 56.9 %, a hypothermia-induced relative risk reduction of poor
neurological function of 7.29 % suggested by all trials, α = 0.05 two-sided, β = 0.20 (power = 80 %), and diversity D2 = 79 %. The cumulated Z-curve
(blue) crosses the traditional boundary (p = 0.05) but not the trial sequential monitoring boundary, indicating lack of firm evidence for a beneficial effect
of 7.29 % relative risk reduction of the intervention when the analysis is adjusted for repetitive testing on accumulating data. There is
insufficient information to reject or detect an intervention effect of 7.29 % relative risk reduction of poor neurological outcome as the
required information size is not yet reached
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Discussion
MIH is one of the most common treatments for patients
who experience CA. However, whether it can improve the
prognosis of patients with CA is still controversial. To fur-
ther evaluate the effects of MIH compared to controls with
temperature >34 °C in adult patients after CA on mortality
and neurologic performance, a meta-analysis of RCTs was
performed. The results suggest that: 1) MIH did not
significantly decrease the mortality at hospital discharge or
at 6 months or 180 days, but it did reduce the mortality of
patients with shockable rhythms at hospital discharge and
at 6 months or 180 days; 2) MIH can improve the out-
come of neurological function at hospital discharge espe-
cially in those patients with shockable rhythm but not at
6 months or 180 days; 3) The incidence of complications
in the MIH group was significantly higher than that in the
control group; 4) All of the intervention effects above
could not be confirmed or rejected by TSA.
Fig. 3 a. Forest plots of the effects of mild induced hypothermia on the mortality at hospital discharge of patients after cardiac arrest. b. Forest
plots of the effects of mild induced hypothermia on the mortality at 6 months or 180 days of patients after cardiac arrest. CI Confidence interval,
HACA Hypothermia After Cardiac Arrest, I2 Percentage of total variation across studies from between-study heterogeneity rather than by chance,
M-H Mantel-Haenszel, MIH mild induced hypothermia
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The results of the meta-analysis were different from
previous studies investigating possible beneficial effects
of MIH after CA. To our knowledge, our study is the
first meta-analysis that separated the patients into
shockable and non-shockable rhythm due to the initial
rhythms. Moreover, our study also included the study by
Nielsen et al. [11] that has a very low risk of bias. In
contrast to the last Cochrane reviews [12], we did not
find a reduced mortality comparing MIH and TTM. Fur-
thermore, Cochrane reviews [12] did not report any
outcome at 6 months. In the meta-analysis by Nielsen et
al. [10] in 2011, the data on main outcomes were also
pooled together. In our meta-analysis, we used TSA to
evaluate type I errors which result from an increased
risk of random error and repeated significance testing.
Heterogeneity in the control group makes this meta-
analysis different from others. It is very clear to demon-
strate the overall effects of MIH but imprecise to state
the influences of the exact range of temperature when
mixing the controls with any body temperature >34 °C
Fig. 4 a. Forest plots of the effects of mild induced hypothermia on neurological function at hospital discharge in patients after cardiac arrest.
b. Forest plots of the effects of mild induced hypothermia on neurological function at 6 months or 180 days in patients after cardiac arrest.
CI Confidence interval, HACA Hypothermia After Cardiac Arrest, I2 Percentage of total variation across studies from between-study heterogeneity
rather than by chance, M-H Mantel-Haenszel, MIH mild induced hypothermia
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Fig. 5 Forest plots of adverse events associated with mild induced hypothermia in patients after cardiac arrest. CI Confidence interval, HACA
Hypothermia After Cardiac Arrest, I2 Percentage of total variation across studies from between-study heterogeneity rather than by chance, M-H
Mantel-Haenszel, MIH mild induced hypothermia
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together. However, when separating the temperature
control into no target temperature and TTM in the sub-
group analysis, it shows that patients treated with MIH
have a better outcome than patients treated with no tar-
get temperature. Because of the heterogeneous control
in the meta-analysis, it does not mean that temperature
does not need to be managed at all for CA patients.
Current 2015 American Heart Association Guidelines
Update for Cardiopulmonary Resuscitation and Emergency
Cardiovascular Care recommend that all comatose adult
patients with ROSC after CA should have TTM, with a tar-
get temperature between 32 °C and 36 °C selected and
achieved, then maintained constantly for at least 24 hours
[23]. Therefore, further trials are needed to elucidate the
optimal target temperature of MIH after CA.
That MIH cannot improve the mortality of patients
with CA may be due to the heterogeneity of pa-
tients. Whole-body low temperature treatment during
Fig. 6 a. Risk of bias graph. Review authors’ judgements about each risk of bias item presented as percentages across all included studies. b. Risk
of bias summary. Review authors’ judgements about each risk of bias item for each included study
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resuscitation may interfere with organ function, and thus
the benefits of MIH should be balanced with its side ef-
fects [24]. Moreover, large differences remain in patients
with CA of different severity, and the potential pros and
cons of temperature intervention are not equivalent in dif-
ferent patients. Recently, a large observational study has
shown that hypothermia was independently associated with
an improved outcome at hospital discharge in patients who
presented with ventricular fibrillation/ventricular tachycar-
dia but not in patients with non-shockable rhythms [25].
Therefore, if the time and degree of hypothermia could
match the severity of the brain injury in patients with CA,
these patients may also benefit from the MIH. However,
these patients were not screened before each study, and a
“one-size-fits-all” treatment approach makes it impossible
to improve the outcomes of patients who require this
treatment.
The selection of the temperature and implementation
time of MIH may also affect the improvement of
neurological function. The primary protective effect of
MIH is to reduce brain metabolism of free radicals, to
inhibit the release of excitatory amino acids, to attenuate
the immune response in reperfusion and to inhibit apop-
tosis of brain cells [26]. Lopez-de-Sa and colleagues have
suggested that a 32 °C cooling level may be associated
with lower mortality and incidence of seizures compared
with that of a 34 °C cooling level in patients who experi-
enced an OHCA secondary to a shockable rhythm [27].
Moreover, in animal models of CA, the implementation
of low temperature treatment (33 °C ± 1 °C in 4 hours
after ROSC) can improve mortality and neurological
function [28, 29]. In addition, it has been demonstrated
that prehospital therapeutic hypothermia after CA can
decrease temperature on hospital admission [30]. There-
fore, a quicker induction of hypothermia may prevent a
cascade effect of reperfusion injury, inflammatory attack
and cell degeneration. However, current guidelines for
CA do not recommend routine prehospital cooling with
Table 2 Summary of findings for the main comparison









Outcomes Anticipated absolute effectsa
(95 % CI)





Risk with control Risk with MIH
Mortality (follow-up 180 days
or hospital discharge)
Study population RR 0.94 (0.84 to 1.04) 1363 (5 RCTs) ⨁◯◯◯ VERY
LOWb c d
510 per 1000 480 per 1000
(429 to 531)
Moderate
551 per 1000 518 per 1000
(463 to 573)
Neurological outcome (follow-up
180 days or hospital discharge)
Study population RR 0.83 (0.68 to 1.01) 1409 (6 RCTs) ⨁◯◯◯ VERY
LOWb c d
569 per 1000 472 per 1000
(387 to 575)
Moderate
671 per 1000 557 per 1000
(456 to 677)
GRADE Working Group grades of evidence: high quality—we are very confident that the true effect lies close to that of the estimate of the effect; moderate
quality—we are moderately confident in the effect estimate (the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different); low quality—our confidence in the effect estimate is limited (the true effect may be substantially different from the estimate of the effect);
very low quality—we have very little confidence in the effect estimate (the true effect is likely to be substantially different from the estimate of effect).
aThe risk in the intervention group (and its 95 % CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its
95 % CI)
bAll trials were with substantial risk of bias
cOne trial accounted for the largest part among all the trials and probably contributed to the heterogeneity
dOne trial included only less than 8 % of the screened patients. One trial included only cardiac arrest patients with pulseless electrical activity and asystole
CI Confidence interval, MIH Mild induced hypothermia, RCT Randomised controlled trial, RR Risk ratio
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Table 3 GRADE profile for assessing quality of evidence for mild induced hypothermia after out-of-hospital cardiac arrest
Quality assessment No. of patients Effect Quality Importance
No. of studies Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations MIH Control Relative (95 % CI) Absolute (95 % CI)
Mortality (follow-up 180 days or hospital discharge)
5 Randomised
trials






31 fewer per 1000





55.1 % 33 fewer per 1000
(from 22 more to
88 fewer)
Neurological outcome (follow-up 180 days or hospital discharge)
6 Randomised
trials






97 fewer per 1000





67.1 % 114 fewer per 1000
(from 7 more to
215 fewer)
GRADE Working Group grades of evidence: high quality—we are very confident that the true effect lies close to that of the estimate of the effect; moderate quality—we are moderately confident in the effect estimate
(the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different); low quality—our confidence in the effect estimate is limited (the true effect may be
substantially different from the estimate of the effect); very low quality—we have very little confidence in the effect estimate (the true effect is likely to be substantially different from the estimate of effect).
aAll trials were with substantial risk of bias
bOne trial accounted for the largest part among all the trials and probably contributed to the heterogeneity
cOne trial included only less than 8 % of the screened patients. One trial included only cardiac arrest patients with pulseless electrical activity and asystole









rapid infusion of cold intravenous fluids after ROSC
[23]. MIH also interferes with numerous physiological
and pathological processes; therefore, MIH might have
unfavourable effects in patients who receive it and po-
tentially put them at risk for adverse events.
Different cooling measurements may cause different
complications and may reduce the efficacy of MIH.
Surface and intravascular (invasive) cooling are the main
measures for induction and maintenance of low body
temperature. Compared with intravascular cooling, sim-
ple surface cooling seems to be associated with greater
temperature fluctuations and more frequent overcooling,
which may result in serious complications [31]. None-
theless, intravascular cooling and surface cooling with
automatic feedback systems allow for a more stable con-
trol of the temperature [32, 33]. Therefore, although no
significant differences were observed in the complica-
tions between the low temperature and the normal
temperature groups in patients with CA [34], the appro-
priate cooling measures could effectively prevent poten-
tial complications associated with MIH. Many cooling
methods currently exist in clinical practice, and the
identification of the most effective and safe methods to
induce hypothermia need to be confirmed by further
research.
The avoidance of post-hypothermia fever (PHF) can
effectively improve the prognosis of patients with CA.
Two large RCTs were included in our meta-analysis,
namely the study by Nielsen et al. [11] and the
Hypothermia After Cardiac Arrest (HACA) study [7].
After a comparison of the two studies, the mortality of
OHCA patients in Nielsen et al.’s study was lower than
that of patients in the HACA study. This is likely related
to control of the body temperature after MIH. Moreover,
that no differences were observed in the outcomes of
the two groups of patients in Nielsen et al.’s study seems
to be associated with a prevention of PHF. In addition,
in older trials of MIH, many patients in the “normother-
mia” group actually became hyperthermic, which is dele-
terious for prognosis and recovery of neurological function
in patients with CA. Bro-Jeppesen and colleagues have
shown that a PHF ≥38.5 °C was associated with an increase
in 30-day mortality, even after controlling for poten-
tial confounding factors [35]. Current guidelines also
show that actively preventing fever in comatose pa-
tients after temperature management is reasonable
[23]. Therefore, effectively avoiding PHF may benefit
patients with CA.
It is worth mentioning that there is lack of firm evi-
dence for a beneficial effect and an insufficient informa-
tion size to reject the anticipated intervention effect.
Thus, the question whether MIH is beneficial, neutral or
harmful, for adult OHCA patients still needs an answer.
Conclusions
In summary, this meta-analysis of the available RCTs
showed that MIH does not improve in- hospital, 6-
month or 180-day mortality in adult patients with CA.
However, it is too early to completely negate the thera-
peutic effects of MIH in patients with CA. Future stud-
ies should pay particular attention to the temperature
and the timing of MIH, selection of patients, efficiency
and security of cooling measures and the avoidance of
PHF. Much more research is needed to optimise the
strategy of MIH.
Key messages
• Mild induced hypothermia is believed to reduce
mortality and neurological impairment after out-of-
hospital cardiac arrest. However, a recently pub-
lished trial did not provide evidence supporting this
hypothesis.
Fig. 7 a. Sensitivity analysis of the effects of mild induced hypothermia on the mortality of patients after cardiac arrest for all included studies.
b. Sensitivity analysis of the effects of mild induced hypothermia on the neurological function of patients after cardiac arrest for all included
studies. CI Confidence interval, HACA Hypothermia After Cardiac Arrest
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• Our study-level meta-analysis shows that treatment
with mild induced hypothermia does not appear to
improve the short-term or long-term mortality of
adult patients with cardiac arrest.
• Mild induced hypothermia may have a possible benefi-
cial effect for patients with shockable rhythms both in
mortality and neurological function.
• Although mild induced hypothermia may result in
some adverse events, it helped lead to better out-
comes regarding neurological function in patients
with cardiac arrest, especially those with shockable
rhythms. Large-scale ongoing trials addressing this
question may provide data better applicable to
clinical practice.
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